ZURICH, June 6 (Reuters) – The following are some of the
main factors expected to affect Swiss stocks on Wednesday.
ROCHE
Roche said on Wednesday that a trial had shown its
rheumatoid arthritis drug RoActemra was more effective in
reducing swelling and tenderness in joints than Abbott
Laboratories’ top-selling Humira when given as a single
treatment.
For more, click on:
NOVARTIS
Patients suffering from the most severe form of childhood
arthritis were less likely to experience a flare up in the
disease when using Novartis’ drug Ilaris compared to a
p la cebo, the Swiss drugmaker said on Wednesday.
For more, click on:
COMPANY STATEMENTS
* Synthes gave provisional notice of delisting
date of its stock on SIX Swiss Exchange.
* Oerlikon said it had signed a syndicated credit
contract for over 800 million Swiss francs with a consortium of
seven international banks.
* The Board of Directors of Liechtensteinische Landesbank AG
has appointed Heinz Knecht as head of the Retail &
Corporate Banking Division, and a member of the Group Executive
Management and LLB Management Board.
* LEM Holding AG said sales reached 55.8 million
Swiss francs in the fourth-quarter of the 2011/2012 financial
year.
* CKW said it had a total operating performance of
498 million Swiss francs in the first half.
ECONOMY
